Literature DB >> 14512094

Antinociceptive interactions of ketamine with morphine or methadone in mononeuropathic rats.

Teresa Pelissier1, Claudio Laurido, Verónica Kramer, Alejandro Hernández, Carlos Paeile.   

Abstract

To study the antinociceptive synergy resulting from the combination of opioid receptor agonists and N-methyl-D-aspartate (NMDA) receptor antagonists on neuropathic pain, an isobolographic analysis of equianalgesic combinations of ketamine with methadone or morphine was performed in rats with mononeuropathy produced by placing four constrictive ligatures around the common sciatic nerve. Two weeks later, the antinociceptive effect of subcutaneous administration of the drugs alone or combined was evaluated by using the paw pressure test. Drugs and their combinations produced dose-dependent antinociception. Combinations produced synergy of a supra-additive nature in the neuropathic paw, but only additive antinociception in the normal paw. The ketamine/methadone combination was more effective to produce antinociception in the neuropathic paw than was the ketamine/morphine association, as revealed by the lower ED25. The results indicate supra-additive synergy between NMDA receptor antagonists and opioids, especially methadone, to produce antinociception in experimental neuropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512094     DOI: 10.1016/s0014-2999(03)02192-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Authors:  Matthew L Banks; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2010-08-03       Impact factor: 3.533

2.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

3.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

Review 4.  [Ketamine in the therapy of chronic pain and depression].

Authors:  Wolfgang Jaksch; Rudolf Likar; Martin Aigner
Journal:  Wien Med Wochenschr       Date:  2019-04-12

Review 5.  Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.

Authors:  Marko A Peltoniemi; Nora M Hagelberg; Klaus T Olkkola; Teijo I Saari
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

6.  Methadone and Ketamine: Boosting Benefits and Still More to Learn.

Authors:  Evan D Kharasch; J David Clark
Journal:  Anesthesiology       Date:  2021-05-01       Impact factor: 7.892

7.  Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383].

Authors:  Adam P Tucker; Yong Ik Kim; Raymond Nadeson; Colin S Goodchild
Journal:  BMC Anesthesiol       Date:  2005-04-02       Impact factor: 2.217

8.  An isobolographic analysis of the antinociceptive effect of xylopic acid in combination with morphine or diclofenac.

Authors:  Eric Woode; Elvis Ofori Ameyaw; Wonder Kofi Mensah Abotsi; Eric Boakye-Gyasi
Journal:  J Basic Clin Pharm       Date:  2015-09

9.  Magnesium Salt, a Simple Strategy to Improve Methadone Analgesia in Chronic Pain: An Isobolographic Preclinical Study in Neuropathic Mice.

Authors:  Valeria González; Teresa Pelissier; Victoria Cazanga; Alejandro Hernández; Luis Constandil
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.